Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

After years of preparation, Eli Lilly is on the brink of launching a fully connected and personalised diabetes management platform, underpinned by digital technologies. The Tempo system brings ...

We recently compiled a list of the 7 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Eli ...

Eli Lilly's latest clinical readout for dual GIP/GLP-1 agonist tirzepatide is a big one, with data suggesting the drug can reduce the risk of developing type 2 diabetes in overweight and obese ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

Eli Lilly has established itself as a powerhouse in the pharmaceutical industry, with a particular focus on diabetes care, oncology, immunology, and neuroscience. The company's recent success has ...

Global pharma major Lupin Limited announced the acquisition of Huminsulin in India from Eli Lilly and Company (Lilly) to further enhance its diabetes portfolio. Lupin has been marketing the Huminsulin ...

With a market cap of $759.4 billion, Eli Lilly operates across diverse therapeutic areas, providing cutting-edge solutions in oncology, diabetes, immunology, and neuroscience. The Indianapolis ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $717.9 billion, has been making waves in the biopharmaceutical industry with its innovative treatments ...